As the DOD's prime contractor, Nanotherapeutics is responsible for establishing and operating a facility that will provide Medical Countermeasures Advanced Development and Manufacturing (MCM-ADM) capabilities to the agency. The goal of the contract is to enable fast and effective development of medical countermeasures that are designed to protect and treat military against chemical, biological, radiological and nuclear attacks and outbreaks of naturally occurring, emerging and genetically engineered infectious diseases.
As the leader of the NANO-ADM Center, Nanotherapeutics will head all Medical Countermeasures (MCM) development and domestic vaccine manufacturing, including "surge capacity," in the event of unforeseen emergencies or disasters. The company will fulfill its responsibilities both in-house and through a teaming network of 16 partners.
When open, the NANO-ADM Center will be available to both the DOD and other third parties, providing access to a state-of-the-art, 165,000-square-foot facility featuring single-use equipment. The Center will integrate new biomanufacturing technologies with existing capabilities, enabling the development of both small-molecule and biologic products. The design includes space for vector development, quality control, a development pilot plant, manufacturing core, a warehouse, office/administration space and utilities.
Designed by RS&H Architects (Jacksonville, Florida), the NANO-ADM will offer flexible, advanced-development capabilities designed to reduce costs and scheduling risks, as well as protect client intellectual property. Eventually, the center will offer its services and capabilities in MCM and infectious disease-vaccine manufacturing to broader customer bases, including other U.S. federal agencies, including the U.S. Department of Health and Human Services, as well as industry.
The Whiting-Turner Contracting Company (Tampa, Florida) began construction of the NANO-ADM in late 2013, and expects completion later this year. The DOD contract could be worth more than $360 million over 10 years. With the addition of the NANO-ADM, Nanotherapeutics will add an estimated 95 jobs, bringing its total number of employees in Florida to 200.
Industrial Info Resources (IIR), with global headquarters in Sugar Land, Texas, five offices in North America and 10 international offices, is the leading provider of global market intelligence specializing in the industrial process, heavy manufacturing and energy markets. Industrial Info's quality-assurance philosophy, the Living Forward Reporting Principle, provides up-to-the-minute intelligence on what's happening now, while constantly keeping track of future opportunities.
Want More IIR News?
Make us a Preferred Source on Google to see more of us when you search.
Add Us On GoogleRefer This Article
Ask Us
Have a question for our staff?
Submit a question and one of our experts will be happy to assist you.
Explore Our EnergyLive Tools
EnergyLive Tools provide instant insight into new build, outages, maintenance, and capacity shifts across key energy sectors.
Learn MoreRelated Articles
-
It's a Wrap! Pharma-Biotech Industry Set To Complete 268 Nor...August 23, 2016
-
Origis Energy Progresses Solar Buildout in Florida, Other Lo...August 09, 2024
-
West Coast, New England Lead in Life Science Capital Project...August 24, 2022
-
Contractor Whiting-Turner at Work on More than $8.7 Billion ...January 08, 2020
Explore Our Enery Industry Reports
Gain the competitive edge with IIR Energy’s suite of energy market reports, designed for traders, analysts, and asset managers who rely on verified, real-time data.
Learn MoreIndustry Intel
-
From Data to Decisions: How IIR Energy Helps Navigate Market VolatilityOn-Demand Podcast / Nov. 18, 2025
-
Navigating the Hydrogen Horizon: Trends in Blue and Green EnergyOn-Demand Podcast / Nov. 3, 2025
-
ESG Trends & Challenges in Latin AmericaOn-Demand Podcast / Nov. 3, 2025
-
2025 European Transportation & Biofuels Spending OutlookOn-Demand Podcast / Oct. 27, 2025
-
2025 Global Oil & Gas Project Spending OutlookOn-Demand Podcast / Oct. 24, 2025